Abraxis Oncology was formed with the philosophy that "we will not be bound by current dogma." As it became clear to us that nanotechnology (the science of molecular particles, measured in nanometersbillionths of a meter) would intersect with cellular biology, molecular biology, and medicine, we made the bold commitment that we would make this convergence happen.

The key to next-generation advances is creativity. That means asking the questions that may at first glance appear completely counter-intuitive:

"Should we be working with tumor biology instead of fighting it?"
"Can we turn a drug into a source of food for the tumor?"
"Could tumor blood supply be our access point?"

We have transformed the highly promising concept of protein-bound particle chemotherapeutics into an exciting new patient reality, a next-generation taxane. Through research, innovative science, and creative thinking we are working to redefine the treatment of cancer as we know it.

At Abraxis Oncology, we are employing the best of the best from multiple disciplines. From our national sales force to our marketing team, to our medical department, to support services, and beyond, we are committed to making a difference.